Prospective, Same-Day, Direct Comparison of Controlled Attenuation Parameter With the M vs the XL Probe in Patients With Nonalcoholic Fatty Liver Disease, Using Magnetic Resonance Imaging-Proton Density Fat Fraction as the Standard

被引:51
作者
Caussy, Cyrielle [1 ,2 ,3 ]
Brissot, Justine [1 ]
Singh, Seema [1 ]
Bassirian, Shirin [1 ]
Hernandez, Carolyn [1 ]
Bettencourt, Ricki [1 ]
Rizo, Emily [1 ]
Richards, Lisa [1 ]
Sirlin, Claude B. [4 ]
Loomba, Rohit [1 ,5 ,6 ]
机构
[1] Univ Calif San Diego, Dept Med, NAFLD Res Ctr, La Jolla, CA 92093 USA
[2] Univ Claude Bernard Lyon 1, Natl Inst Appl Sci Lyon, INRA U1397, CarMen Lab,INSERM U1060, Pierre Benite, France
[3] Hosp Civils Lyon, Dept Endocrinol Diabet & Nutr, Hop Lyon Sud, Pierre Benite, CA, France
[4] Univ Calif San Diego, Dept Radiol, Liver Imaging Grp, La Jolla, CA 92093 USA
[5] Univ Calif San Diego, Dept Med, Div Gastroenterol, La Jolla, CA 92093 USA
[6] Univ Calif San Diego, Div Epidemiol, Dept Family & Prevent Med, La Jolla, CA 92093 USA
基金
美国国家卫生研究院;
关键词
FibroScan; Liver Fat; NASH; Diagnostic; HEPATIC STEATOSIS; NONINVASIVE EVALUATION; QUANTIFICATION; ELASTOGRAPHY; HISTOLOGY; FIBROSIS; CAP; MRI;
D O I
10.1016/j.cgh.2019.11.060
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
BACKGROUND & AIMS: Controlled attenuation parameter (CAP) measurements using M probe have been reported to be lower than those of the XL-probe in detection of hepatic steatosis. However, there has been no direct comparison of CAP with the M vs the XL probe in patients with nonalcoholic fatty liver disease (NAFLD). We compared CAP with the M vs the XL probe for quantification of hepatic fat content, using magnetic resonance imaging proton density fat fraction (MRI-PDFF) as the standard. METHODS: We performed a prospective study of 100 adults (mean body mass index [BMI], 30.6 +/- 4.7 kg/m2) with and without NAFLD, assessed by CAP with the M probe and XL probe on the same day, at a single research center, from November 2017 through November 2018. We then measured the MRI-PDFF as the reference standard. Outcomes were presence of hepatic steatosis, defined as MRI-PDFF >= 5%, and detection of hepatic fat content >= 10%, defined as MRI-PDFF >= 10%. We performed area under the receiver operating characteristic curve (AUROC) analyses to assess the diagnostic accuracy of CAP for each probe in detection of hepatic steatosis (MRI-PDFF >= 5%) and of hepatic fat content >= 10%. RESULTS: Of the study participants, 68% had an MRI-PDFF of 5% or more and 48% had an MRI-PDFF of 10% or more. The mean CAP measured by the M probe (310 +/- 62 db/m) was significantly lower than by the X probe (317 +/- 63 db/m) (P = .007). When M probe was used in participants with BMIs <30 kg/m(2) and XL probe in participants with BMIs >= 30 kg/m(2), the CAP measured by the M probe (312 +/- 51.4 db/m) remained significantly lower than that of the XL probe (345 +/- 47.6 db/m) (P = .0035.), when the MRI-PDFF was above 5%. The optimal threshold of CAP for the detection of MRI-PDFF >= 5%, was 294 db/m with the M probe and 307 db/m with the XL probe. The optimal threshold of CAP for the detection of MRI-PDFF >= 10%, was 311 db/m with the M probe and 322 db/m with the XL probe. For only the XL probe, CAP measurements with an interquartile range below 30 dB/m detected an MRI-PDFF >= 5% with a lower AUROC (0.97; 95% CI, 0.80-1.00) than CAP measurements with an interquartile range above 30 dB/m (AUROC, 0.82; 95% CI, 0.71-0.90) (P = .0129). CONCLUSIONS: In an analysis of the same patients using CAP with the M probe and XL probe, with MRI-PDFF as the standard, we found that the M probe under-quantifies CAP values compared with the XL probe, independent of BMI. The type of probe should be considered when interpreting CAP data from patients with NAFLD.
引用
收藏
页码:1842 / +
页数:15
相关论文
共 30 条
[1]   Liver Stiffness Measurement With FibroScan: Use the Right Probe in the Right Conditions! [J].
Berger, Arthur ;
Shili, Sarah ;
Zuberbuhler, Floraine ;
Hiriart, Jean-Baptiste ;
Lannes, Adrien ;
Chermak, Faiza ;
Hunault, Gilles ;
Foucher, Juliette ;
Oberti, Frederic ;
Fouchard-Hubert, Isabelle ;
Cales, Paul ;
de Ledinghen, Victor ;
Boursier, Jerome .
CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2019, 10
[2]   Non-invasive evaluation of liver fibrosis using transient elastography [J].
Castera, Laurent ;
Forns, Xavier ;
Alberti, Alfredo .
JOURNAL OF HEPATOLOGY, 2008, 48 (05) :835-847
[3]   A gut microbiome signature for cirrhosis due to nonalcoholic fatty liver disease [J].
Caussy, Cyrielle ;
Tripathi, Anupriya ;
Humphrey, Greg ;
Bassirian, Shirin ;
Singh, Seema ;
Faulkner, Claire ;
Bettencourt, Ricki ;
Rizo, Emily ;
Richards, Lisa ;
Xu, Zhenjiang Z. ;
Downes, Michael R. ;
Evans, Ronald M. ;
Brenner, David A. ;
Sirlin, Claude B. ;
Knight, Rob ;
Loomba, Rohit .
NATURE COMMUNICATIONS, 2019, 10 (1)
[4]   Collagen Formation Assessed by N-Terminal Propeptide of Type 3 Procollagen Is a Heritable Trait and Is Associated With Liver Fibrosis Assessed by Magnetic Resonance Elastography [J].
Caussy, Cyrielle ;
Bhargava, Meera ;
Villesen, Ida F. ;
Gudmann, Natasja S. ;
Leeming, Diana J. ;
Karsdal, Morten A. ;
Faulkner, Claire ;
Bao, Denny ;
Liu, Amy ;
Lo, Min-Tzu ;
Bettencourt, Ricki ;
Bassirian, Shirin ;
Richards, Lisa ;
Brenner, David A. ;
Chen, Chi-Hua ;
Sirlin, Claude B. ;
Loomba, Rohit .
HEPATOLOGY, 2019, 70 (01) :127-141
[5]   Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease [J].
Caussy, Cyrielle ;
Ajmera, Veeral H. ;
Puri, Puneet ;
Hsu, Cynthia Li-Shin ;
Bassirian, Shirin ;
Mgdsyan, Mania ;
Singh, Seema ;
Faulkner, Claire ;
Valasek, Mark A. ;
Rizo, Emily ;
Richards, Lisa ;
Brenner, David A. ;
Sirlin, Claude B. ;
Sanyal, Arun J. ;
Loomba, Rohit .
GUT, 2019, 68 (10) :1884-1892
[6]   Noninvasive, Quantitative Assessment of Liver Fat by MRI-PDFF as an Endpoint in NASH Trials [J].
Caussy, Cyrielle ;
Reeder, Scott B. ;
Sirlin, Claude B. ;
Loomba, Rohit .
HEPATOLOGY, 2018, 68 (02) :763-772
[7]   Optimal threshold of controlled attenuation parameter with MRI-PDFF as the gold standard for the detection of hepatic steatosis [J].
Caussy, Cyrielle ;
Alquiraish, Mosab H. ;
Nguyen, Phirum ;
Hernandez, Carolyn ;
Cepin, Sandra ;
Fortney, Lynda E. ;
Ajmera, Veeral ;
Bettencourt, Ricki ;
Collier, Summer ;
Hooker, Jonathan ;
Sy, Ethan ;
Rizo, Emily ;
Richards, Lisa ;
Sirlin, Claude B. ;
Loomba, Rohit .
HEPATOLOGY, 2018, 67 (04) :1348-1359
[8]   Nonalcoholic fatty liver disease with cirrhosis increases familial risk for advanced fibrosis [J].
Caussy, Cyrielle ;
Soni, Meera ;
Cui, Jeffrey ;
Bettencourt, Ricki ;
Schork, Nicholas ;
Chen, Chi-Hua ;
Al Ikhwan, Mahdi ;
Bassirian, Shirin ;
Cepin, Sandra ;
Gonzalez, Monica P. ;
Mendler, Michel ;
Kono, Yuko ;
Vodkin, Irine ;
Mekeel, Kristin ;
Haldorson, Jeffrey ;
Hemming, Alan ;
Andrews, Barbara ;
Salotti, Joanie ;
Richards, Lisa ;
Brenner, David A. ;
Sirlin, Claude B. ;
Loomba, Rohit .
JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (07) :2697-2704
[9]   Can the same controlled attenuation parameter cut-offs be used for M and XL probes for diagnosing hepatic steatosis? [J].
Chan, Wah-Kheong ;
Mustapha, Nik Raihan Nik ;
Mahadeva, Sanjiv ;
Wong, Vincent Wai-Sun ;
Cheng, Jenny Yeuk-Ki ;
Wong, Grace Lai-Hung .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2018, 33 (10) :1787-1794
[10]   Controlled attenuation parameter using the FibroScan® XL probe for quantification of hepatic steatosis for non-alcoholic fatty liver disease in an Asian population [J].
Chan, Wah-Kheong ;
Mustapha, Nik Raihan Nik ;
Wong, Grace Lai-Hung ;
Wong, Vincent Wai-Sun ;
Mahadeva, Sanjiv .
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL, 2017, 5 (01) :76-85